Pet Monoclonal Antibodies Market Analysis

Pet Monoclonal Antibodies Market Analysis

To get key market trends

  Download Free Sample

Based on animal, the market is categorized as dogs and cats. The dogs segment is set to lead the market, accounting for the largest revenue of USD 715.9 million in 2023, anticipating its dominance throughout the forecast period with a CAGR of 14.1%.
 

• The dogs segment dominated the market due to the high prevalence of chronic and infectious diseases among dogs, necessitating advanced treatments.
   
• The pet owners' increasing willingness to invest in the health and well-being of their dogs, coupled with the availability of targeted monoclonal antibody therapies, has significantly driven this market segment.
   
• Additionally, the growing number of pet dogs and the rising trend of pet humanization have further fueled the demand for effective and specialized treatments, consolidating the dominance of the dogs segment in the market.
   

Based on application the pet monoclonal antibodies market is classified into dermatology, osteoarthritis, cancer, and other applications. The dermatology segment holds the largest market share of 48.9% in 2023 and is expected to maintain dominance throughout the analysis period.
 

• The dermatology segment dominance was asserted due to the high prevalence of skin conditions and allergies among pets. For instance, a study published in the Veterinary Sciences Journal in July 2022 found that atopic dermatitis (AD) is one of the most common pet allergies. In dogs, the prevalence of AD has increased due to greater exposure to indoor environments and processed pet foods. Consequently, the growing burden of AD among dogs spurred the demand for veterinary dermatology drugs, thereby fueling the growth of monoclonal antibodies anticipating opportunities in the market.
   
• In addition, the growing awareness among pet owners about the importance of treating dermatological issues, combined with the effectiveness of monoclonal antibodies in providing targeted and long-lasting relief, has driven this segment's growth.
   
• Thus, the aforementioned factors are expected to supplement the segmental growth.
   

Based on the end-user, the pet monoclonal antibodies market is segmented into veterinary hospitals, veterinary clinics, and academics and research institutes. The veterinary hospitals segment dominated the market with the highest share in 2023.
 

• Veterinary hospitals dominance was asserted by their comprehensive range of services and advanced medical facilities, which attract pet owners seeking high-quality care for their animals.
   
• These hospitals are equipped with specialized diagnostic and treatment capabilities, including the administration of monoclonal antibody therapies.
   
• The expertise of veterinary professionals and the availability of cutting-edge treatments in these hospitals make them the preferred choice for managing complex and chronic conditions in pets.
   
• As a result, the veterinary hospital's segment has seen significant growth and has become a leading segment in the market.
   

The U.S. dominated the North American pet monoclonal antibodies market accounting for USD 432.9 million in 2023 and is anticipated to show considerable growth over the analysis period.
 

• The country’s prominence was attributed by high pet ownership rates, and significant investment in R&D. Also, high veterinary healthcare spending in the U.S. tends to further expand the market.
   
• For instance, according to the American Pet Products Association, in 2022, pet owners spent USD 31.5 billion on supplies, live animals, and medicine, and USD 35.9 billion on veterinary care and products. Thus, the increasing expenditure on veterinary care is driving the demand for effective treatment options, thereby propelling market growth.
   
• Additionally, strong support from regulatory bodies such as the FDA for clinical trials and product approvals further bolsters the U.S. market's growth and innovation.
   

Germany exhibited a high growth potential in the European pet monoclonal antibodies market.
 

• Germany is a key player in the market in Europe, known for its advanced veterinary care and stringent regulatory standards.
   
• The country's emphasis on research and technological innovation in veterinary sciences supports the development and adoption of targeted therapies for the treatments.
   
• In addition, growing awareness among pet owners about advanced therapies and the presence of leading veterinary research institutions and biotechnology companies contribute to Germany's significant role in the market.
   

The Asia Pacific pet monoclonal antibodies market is poised for rapid growth with a CAGR of 14.8% during the forecast period.

• The Asia Pacific market is poised for rapid growth due to increasing pet ownership, rising awareness about advanced veterinary treatments, and growing animal healthcare expenditure.
   
• Growing investment in veterinary healthcare is driving research for targeted therapies. Also, advancements in biotechnology and a growing focus on animal health are propelling the adoption of innovative treatments.